<h2 dir="ltr">Metastatic HR+/HER2&minus; Breast Cancer</h2>
<a href="https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market">Metastatic HR+/HER2&minus; Breast Cancer</a> is the most common subtype of breast cancer, characterized by cancer cells expressing hormone receptors for estrogen and progesterone while lacking HER2 overexpression.
<h3 dir="ltr">Metastatic HR+/HER2&minus; Breast Cancer Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" role="presentation">Total Incidence Cases of Breast Cancer </li>
<li dir="ltr" role="presentation">Total Incident Cases of HER2-positive Breast Cancer </li>
<li dir="ltr" role="presentation">Hormonal Status of HER2-positive Breast Cancer </li>
<li dir="ltr" role="presentation">Age-specific Cases of HER2-positive Breast Cancer </li>
<li dir="ltr" role="presentation">Stage-specific Cases of HER2-positive Breast Cancer </li>
<li dir="ltr" role="presentation">Line-wise Metastatic Cases of HER2-positive Breast Cancer</li>
</ul>
<h2 dir="ltr">Metastatic HR+/HER2&minus; Breast Cancer Epidemiology</h2>
<ul>
<li dir="ltr" aria-level="1">
The total incident population of HER2-positive breast cancer in the 7MM was estimated at approximately 104K cases in 2025.
</li>
<li dir="ltr" aria-level="1">
The treatment-eligible pool for HER2-positive breast cancer in the United States was estimated at approximately 14.5K cases in 2025.
</li>
<li dir="ltr" aria-level="1">
Approximately 52% of the total HER2-positive breast cancer cases were accounted for by individuals between 40 and 60 years of age.
</li>
<li dir="ltr" aria-level="1">
Stage-specific incidence of HER2-positive breast cancer in the 7MM was distributed as Stage I &ndash; 37%, Stage II &ndash; 40%, Stage III &ndash; 15%, and Stage IV &ndash; 8%.
</li>
<li dir="ltr" aria-level="1">
The growing burden of metastatic HER2-positive breast cancer, combined with improved biomarker testing and increasing awareness regarding HER2-targeted treatment strategies, is expected to contribute to continued growth in diagnosed and treated cases during the forecast period.
</li>
</ul>
<h2 dir="ltr">Metastatic HR+/HER2&minus; Breast Cancer Market</h2>
<ul>
<li dir="ltr" aria-level="1">
The metastatic HER2-positive breast cancer market size in the 7MM was estimated at approximately USD 2.9 billion in 2025.
</li>
<li dir="ltr" aria-level="1">
The metastatic HER2-positive breast cancer market is expected to grow at a CAGR of 8.3% during the forecast period from 2026 to 2036.
</li>
<li dir="ltr" aria-level="1">
The growth of the market is expected to be driven by the rising disease burden, increasing uptake of HER2-targeted therapies, expansion of premium novel therapies, and growing healthcare spending globally.
</li>
<li dir="ltr" aria-level="1">
The introduction of antibody-drug conjugates (ADCs) has significantly transformed the treatment landscape of metastatic HER2-positive breast cancer, with KADCYLA becoming the first FDA-approved ADC for breast cancer treatment.
</li>
<li dir="ltr" aria-level="1">
Anti-HER2 therapies such as HERCEPTIN, PERJETA, KADCYLA, ENHERTU, and others have substantially improved treatment outcomes in HER2-positive cancers, which were historically associated with aggressive disease progression and poor prognosis.
</li>
<li dir="ltr" aria-level="1">
The market is further expected to benefit from the development of next-generation HER2-targeted therapies designed to overcome resistance and improve progression-free survival in advanced treatment settings.
</li>
</ul>
<h3 dir="ltr">Metastatic HR+/HER2&minus; Breast Cancer Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Rising disease burden and expanding patient pool are driving demand for advanced HER2-targeted therapies.
</li>
<li dir="ltr" aria-level="1">
Strong uptake of HER2-targeted biologics and antibody-drug conjugates continues to support market growth.
</li>
<li dir="ltr" aria-level="1">
The shift toward premium novel therapies with improved efficacy profiles is accelerating adoption in metastatic settings.
</li>
<li dir="ltr" aria-level="1">
Increasing healthcare spending and broader access to precision oncology treatments are contributing to market expansion.
</li>
</ul>
<h3 dir="ltr">Metastatic HR+/HER2&minus; Breast Cancer Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Resistance to antibody-drug conjugates remains a major clinical challenge in advanced HER2-positive breast cancer management.
</li>
<li dir="ltr" aria-level="1">
Managing toxicity associated with HER2-targeted therapies and ADCs continues to impact treatment optimization.
</li>
<li dir="ltr" aria-level="1">
The lack of highly predictive biomarkers for treatment response in advanced disease settings limits precision treatment selection.
</li>
<li dir="ltr" aria-level="1">
Patent expirations for blockbuster therapies such as HERCEPTIN, PERJETA, and KADCYLA, along with increasing biosimilar competition, may restrain market growth during the forecast period.
</li>
</ul>
<h3 dir="ltr">Emerging Metastatic HR+/HER2&minus; Breast Cancer Drugs</h3>
<ul>
<li dir="ltr" aria-level="1">
SYD985 (Trastuzumab duocarmazine)
</li>
<li dir="ltr" aria-level="1">
ARX788
</li>
<li dir="ltr" aria-level="1">
BDC-1001 &plusmn; pertuzumab
</li>
<li dir="ltr" aria-level="1">
BI-1607 + Trastuzumab
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
<h3 dir="ltr">Key Metastatic HR+/HER2&minus; Breast Cancer Companies</h3>
<ul>
<li dir="ltr" aria-level="1">
Roche
</li>
<li dir="ltr" aria-level="1">
Chugai
</li>
<li dir="ltr" aria-level="1">
Daiichi Sankyo
</li>
<li dir="ltr" aria-level="1">
AstraZeneca
</li>
<li dir="ltr" aria-level="1">
Seagen
</li>
<li dir="ltr" aria-level="1">
MacroGenics
</li>
<li dir="ltr" aria-level="1">
Pfizer
</li>
<li dir="ltr" aria-level="1">
Ambrx
</li>
<li dir="ltr" aria-level="1">
Bolt Biotherapeutics
</li>
<li dir="ltr" aria-level="1">
BioInvent International AB
</li>
<li dir="ltr" aria-level="1">
Byondis
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
&nbsp;

Metastatic HER2 positive Breast Cancer Market Infographics

Metastatic HER2 positive Breast Cancer Market Infographic

Explore key insights into the Metastatic HER2-positive Breast Cancer Market through comprehensive infographics, covering market trends, epidemiology, treatment landscape, emerging therapies, and future growth outlook.